Choroid plexus cell replacement therapy - Living Cell Technologies

Drug Profile

Choroid plexus cell replacement therapy - Living Cell Technologies

Alternative Names: Neurological disorders cell therapy - Living Cell Technologies; NeurotrophinCell; NTCELL

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Living Cell Technologies
  • Class Antiparkinsonians; Cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • Preclinical Wounds
  • No development reported Hearing loss; Huntington's disease; Osteoarthritis; Osteoporosis; Retinal disorders; Spinal cord injuries; Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hearing loss in Australia (Intrastriatal, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in New Zealand (Intrastriatal, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Intrastriatal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top